The Atlanta-based biotech company, founded in 2018, focuses on inhibiting vasoactive intestinal peptides (VIP) to treat various cancers. By using inhibitory peptides against immuno-suppressive VIP, Cambium Oncology's licensed technology activates and proliferates T cells, resulting in a cytotoxic T-cell mediated immune response that reduces tumor size and increases survival time. Their small-molecule peptide drugs offer improved anti-tumor activity in multiple cancer models, including pancreatic cancer, melanoma, and leukemia.